Kairos Pharma (KAPA) vs PRF Technologies (PRFX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kairos Pharma is the larger company by market cap ($3.2 million vs $3.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | KAPA | PRFX |
|---|---|---|
| Share price | $0.945 | $0.8798 |
| Market cap | $3.20M | $3.08M |
| 1-day change | +8.57% | +0.24% |
| EPS (TTM) | $-1.96 | $-4.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.59 | $7.95 |
| 52-week low | $0.848 | $0.852 |
| Distance from 52-week high | -90.15% | -88.93% |
| Average volume | 512.51K | 298.86K |
| Shares outstanding | 3.39M | 3.50M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
KAPA vs PRFX FAQ
Which is bigger, Kairos Pharma or PRF Technologies?
Kairos Pharma (KAPA) is larger, with a market capitalization of $3.20M compared with $3.08M for PRF Technologies (PRFX).
Are Kairos Pharma and PRF Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.